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Abstract 
In the present paper we determined the presence of sibutramine in urine using the GC-
MS/MS system. The determination of sibutramine was studied in relation to slimming health 
foods1. Prolonged or excessive consumption of unauthorized pharmaceuticals may cause 
serious adverse consequences on health. In this study, samples were extracted with the help of 
methanol and acetonitryl and the sibutramine concentrations were found in the range of  
0,5 g/l. 
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Introduction 
Amphetamines are psychostimulant drugs that produce increased wakefulness, 
decreased fatigue and appetite.  
The pressor effect of amphetamine was first described by Piness and associates 
(1933). In 1933, it was noted that it is a bronchodilator, a respiratory stimulant with 
analeptic action and was compared to epinephrine. Amphetamines described as 
methamphetamine and dextroamphetamine belongs to the group of drugs that potentially 
increase the levels of norepinephrine, serotonin and dopamine, euphoria-inducing drugs 
absorbed at cellular level. 
From a medical perspective, amphetamines are sympathomimetic substances, related 
to derivatives of adrenaline (epinephrine) in which central excitatory effects prevail. 
Amphetamine is a stimulant of the nervous system due to its weak and long-term pressor 
action (approximately ten times longer than that of adrenaline).  
Amphetamine was first synthesized in 1887 by the Romanian Lazar Edeleanu in 
Berlin, Germany. The name derives from phenylisopropylamine. It was one of a series of 
compounds obtained from plants ephedrine was derived from, that had been isolated by Ma 
Huang together with Nagayoshi Nagai.  
Adrenaline and noradrenaline are hormones secreted by the adrenal glands, located 
in the upper pole of the kidney, and more specifically, the renal medulla. Both hormones exert 
similar effects of sympathetic stimulation, but while norepinephrine has more intense vascular 
actions, adrenaline activates especially the energy metabolism.  
Amphetamine activity at the brain level is specific; certain receptors that respond to 
amphetamine in several brain regions do not conduct the impulse to other regions, although 
they exert effects on behaviour by carrying neurotransmitters in the brain, including 
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dopamine, serotonin and norepinephrine. So dopamine D2 receptors in the hippocampus – the 
brain region associated with memory formation – appear not to be affected by the presence of 
amphetamines. 
I.1. CHEMICHAL STRUCTURE 
In terms of illicit production, alongside amphetamine, the following are obtained:  
- Specific chemical (the chemical used as green material, precursor, reagent or solvent 
in illegal processes or substance control).  
- Precursor (chemicals which in clandestine processes are incorporated, in full or in 
part, in the final production of the molecule of the substance under international control).  
-Reagent (chemical that reacts or participates in the reaction, but does not become part 
of the final product).  
- Solvent (is the liquid substance that dissolves another solid substance without 
changing the chemical composition, and does not become part of the final product).  
- Impurities (natural constituents originating from plant materials or from materials 
obtained through the processing of those remaining in the final product after complete process 
conversion).  
- Adulterants (pharmacologically active substances remaining or added after the 
conversion of the final product).  
- Diluent (pharmacologically inactive substance added to the final product to increase 
volume).  
Amphetamines belong to the class of phenylalkylamines and classify into:  
Amphetamines (found under the following names: 1-phenylpropan-2-amine,  
 methyl-benzeneethanamine  
 methylphenethylamine)  
  Methamphetamine (found under the following names:  
2-(methylamino)-1-phenyl-1-propanone 
N,dimethylaminobenzene 
N,  dimethylphenethyl-benzene  
N-methyl-amphethamine  
Phenylisopropylmethylamine)  
Sibutramine (found under the following names: Meridia, Ectiva, Reductil,  
1-[1-(4-chlorophenyl) cyclo-butyl]-NH,3-trimethyl-butane-1-amine)  
Methylphenidate (found under the following names: centedrin, ritalin)  
Amfepramone (found under the name: Diethylpropion amphetamine)  
Fenfluramine (found under the name: fenfluramine)  
 
I.2. SYNTHESIS  
Amphetamine is prepared from benzyl-methyl-ketone, by using several methods 
commonly used to convert the carbonyl group into the group – CH2NH2 (reduction of the 
nitrogen functional derivatives of carbonyl compounds). Benzyl-methyl-ketone is obtained by 
heating a mixture of phenylacetic acid and acetic acid at 400 C, in the presence of thorium 
dioxide or through the Friedel – Crafts reaction between benzene and chloroacetone, in the 
presence of aluminum chloride. 
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C6H5COOH CH3COOH+
ThO2
400C
C6H5CH2COCH3
C6H6 +
AlCl3ClCH2COCH3
 
 
I.3. FORMULATION 
Amphetamine-products generally come in the form of sulfates or phosphates. They are 
available on the international market in the form of tablets, capsules, syrups and elixirs. The 
vast majority of amphetamines appear as hydrochlorides or sulfates.  
In terms of solubility, amphetamines are insoluble in water. As free bases they are 
soluble in organic solvents such as ethanol, diethyl ether, and chloroform. Hydrochlorides are 
soluble in water and ethanol, slightly soluble in chloroform and insoluble in diethyl ether. 
Sulphates and phosphates are soluble in water, slightly soluble in ethanol and insoluble in 
diethyl ether and chloroform. Trimethylamphetamine have boiling points ranging between 
118 C - 220 C. 
 Amphetamine has two optical isomers:  
- Dextroamphetamine – dextrorotatory stereoisomer  
- Levoamphetamine – levorotary stereoisomer  
Dexamphetamine is 2-4 times more active than the racemic compound as a 
psychomotor stimulant and less active as sympathomimetic. Also the dextrorotatory isomer is 
24 times more active than its levorotary enantiomer.  
Methamphetamine has amphetamine-like properties but its sympathomimetic effects 
are weak in normal doses.  
Methylphenidate is a chemical related to amphetamines, having weaker psychomotor 
stimulant properties and weak peripheral actions. The effect is fast and relatively short in 
duration, corresponding to a half-life of 1-2 hours, which is an advantage over amphetamine. 
Fenfluramine is a halogenated amphetamine derivative. Amphetamines may react with 
H3PO4 and H2SO4 forming amphetamine sulphate and phosphate. Amphetamine derivatives 
are:  
A. Dimethoxy-amphetamines -2.5-dimethoxy-amphetamine (DMA)  
-4bromo-2.5- dimethoxy-amphetamine (DOB)  
- 2.5-dimethoxy-4-methylamphetamine (STP, DOM)  
- 3.4 - methylenedioxyamphetamine  
- 1-methoxy-4-amphetamine  
- dimethoxy-2, 5-ethyl-4-amphetamine 
- methoxy-3-methylenedioxy-4,5-amphetamine  
 
B. Trimethoxy-amphetamines - 3,4,5-trimethoxyamphetamine (TMA 1)  
- 2,4,5-trimethoxyamphetamine (TMA 2)  
- 2,3,4-trimethoxyamphetamine (TMA 3)  
- 2,3,5-trimethoxyamphetamine (TMA 4)  
- 2,3,4-trimethoxyphenyl-propan-2-amine  
- 2,3,6-trimethoxyamphetamine (TMA 5)  
- 2,4,6- trimethoxyphenyl-propane (TMA 6) 
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I.4 CHEMICHAL DETERMINATION  
The most common methods for the determination of amphetamines in biological 
products are spectrophotometric, immunologic fluorescence - FPIA (Fluorescence 
Polarisation Imunoassay), immunochromatographic, gas or liquid chromatography. These 
include: 
I.5.1. The spectrophotometric method – in this case, amphetamine engage, in alkaline 
medium, with diazotized p-nitroaniline resulting in a calorimetric red azo-derivative.  
I.5.2. The immunofluorescence method – is used in screening tests for testing a group 
of subjects suspected of amphetamine or methamphetamine consumption, using urine as a 
bioassay. For an amount of urine of 150 µl/ determination, results are obtained in a period of 
12 to 14 minutes. Results are given as present or absent, because of the methods implemented 
using a six point-calibration curve, rather than a 1-point calibration for the FPIA assay system 
– the cut-off value being used for the determination of xenobiotic substances in the urine by 
reading the light polarization vector in polarization milliunits. A positive result will be 
necessarily confirmed by the GC-MS method.  
I.5.3. Immunochromatographic method – is the appearance of a coloured band on a 
solid support (one to check, another to validate the presence or absence of amphetamines or 
methamphetamines in the urine, saliva or sweat, the type of biological fluids depending on the 
manufacturer of the immunochromatographic test). It also uses urine to detect: opiates, 
cocaine, phencyclidine, cannabis, barbiturates, benzodiazepines, tricyclic antidepressants. A 
positive result will be necessarily confirmed by the GC-MS method.  
I.5.4. The gas-chromatographic method coupled with the GC-MS mass 
spectrophotometer  
I.5.5. The HPLC-MS – DAD method 
II. EXPERIMENTAL 
II.1 Materials  
To determine the amphetamines- sibutramine in this case the following materials were 
used:  
- Spectrophotometer Cary 5 - Varian  
- FPIA AXSYM - Abbot system 
- GC-MS/MS Saturn 2000 - Varian system 
- HPLC-MS/MS-DAD system - Varian  
- Eppendorf centrifuge 5616  
- Analytical balance - Precisa 40SM-200A 
- Magnetic stirrer - HP 240  
- Ultrasonic bath - Branson 2210  
- Thermostat - Memmert 
- Accessories and reagents specific to an analytical toxicology laboratory  
- Sibutramine (10 mg amphetamine - Zentiva)  
Sibutramine (trade name Meridia in the U.S. and Canada, Ectiva in South Africa, 
Reductil in Europe and most other countries), is an orally administered agent for the treatment 
of obesity as an appetite suppressant. It has virtually no potential for abuse because of the lack 
of dopaminergic effects. It is used as an anorexic, which is the only reason for its 
classification as a controlled drug, as in the mid-20th century it resulted in a number of cases 
of abuse or addiction.  
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II.2. METHODS  
II.2.1. Gas chromatography method coupled with the GC-MS mass spectrometer  
It consists of three submethods for each device that is part of the GC-MS system. Thus 
there will be a method for autosampler 8200, one for gas chromatograph 3800 and one for 
mass spectrometer Saturn 2000.  
Autosampler 8200  
Number of containers – 48; Volume injection syringe – 10 µl 
Number of liquids for washing injection syringe – 2  
Time for washing injection syringe with a washer fluid – 20 s  
Time of taking over the injection matrix – between air plugs  
Injection volume – 1 µl; Depth of penetration of the needle into the bottle – 80%  
Fluid intake speed – 1 µl/ s; Heating time for the needle in the injector– 6 s  
Injection speed – 10 µl / s; Time of the needle remaining in the injector after 
injection– 6 s  
Gas chromatography 3800  
Injector type 1079; Injection temperature – 3000C  
Split rate 5% constant for the duration of the analysis; Constant flow – 1.2 ml/min  
Oven temperature program, T0 – 1800C waiting time 1.1 min 
Growth in T1 - 2900C with 50C/min speed; T1 – 2900C waiting time – 13.9 min  
Saturn 2000  
Filament off – 0 – 3min, AGC field "full scan" – 50 – 400 amu; Time 3 – 35 min  
Scan duration – 1s/scan; Filament current – 10 µA; Maximum number of ions 25,000 
Ionization maximum duration 25 ms; Prescan duration 100 µs  
Mass to lower fund – 45 amu 
 
III. RESULTS  
In the conditions mentioned, sibutramine extracted by two methods from a capsule of 
10 mg Amphetamine – Zentiva was highlighted. 
The extraction was performed from 7.5 mg excipient in methanol and acetonytril 1: 1 
and 7.5 mg excipient in dichloroethane, dichloromethane and chloroform 1: 1: 1. The 
solutions were ultrasonated for one hour and centrifuged for 10 minutes. The supernatant was 
the injection matrix for both the gas chromatographic and the HPLC methods. Fig. 1 shows 
the resulting total ion chromatogram following the injection of sibutramine solution with a 
concentration of 0.5 mg/l. 
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Chromatogram Plot
File: \\saturn2000\hdd saturn2\saturn\data\prb24664.ms
Sample: URINA                                         6/16/09 1:19 PM
Sample Notes: SIBUTRAMINE (EXTRACTIE IN TEI SOLVENTI)                         
Operator: MIHAI               Scan Range: 1 - 3000 Time Range: 0.01 - 50.00 min.
12.5 15.0 17.5 20.0 22.5 25.0
minutes
0.00
0.25
0.50
0.75
1.00
MCounts RIC all PRB24664.MS
Sibutramine 0.5 g/l
1
 
Fig. 1. Total ion chromatogram of sibutramine at a concentration of 0.5 g/l. 
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Saturn Purity Search Hit List
Saturn Purity Search Results
Hits Found: 25
Pre-Search Hits Found: 765
Saturn Purity Search Parameters
Threshold: 100
Target Ion Range: 50 - 600
Library MW Range: 50 - 600
Library Ion Range: All of Library Entry
Local Normalization: Off
Requested Pre-Search: 250
Requested Final Search: 25
Search 7 Libraries: A. c:\saturnws\satlib\nist98m.lbr
B. c:\saturnws\satlib\nist98r.lbr
C. c:\saturnws\satlib\pmw.lbr
D. c:\saturnws\satlib\libr_tr.lbr
E. c:\saturnws\satlib\libr_tx.lbr
F. c:\saturnws\satlib\libr_gp.lbr
G. c:\program files\wiley\wiley6.lbr
Target Spectrum
100 200 300 400 500 600
m/z
0%
25%
50%
75%
100%
72
114
137 194 222 280
Target
18.933 min. Scan: 1136 Chan: 1 Ion: 274 us RIC: 1182101 BCBP 114 (652630=100%) PRB24664.MS
Spectrum from \\Saturn2000\hdd saturn2\Saturn\DATA\PRB24664.MS
Scan No: 1136,  Time: 18.933 minutes
No averaging.  Background corrected.
Comment: 18.933 min. Scan: 1136 Chan: 1 Ion: 274 us RIC: 1182101 BC  
Pair Count: 99   MW: 0   Formula: None   CAS No: None  Acquired Range: 50 - 282
   Purity  Fit  RFit Entry #  MW. Formula, CAS No., Name
 1. 925  965  938   8741 C  280 C17H26ClN, 106650-56-0, Sibutramine                         
 2.  698  890  754  51423 A  380 C18H40N2S3, None, Ethane, 1-[(2-diisopropylamino)ethylthio
 3. 663  850  763  51413 A  517 C27H30Cl3N3O, None, 1-[[2-[Butylamino]butyl]imino]-7-chloro-
 4.  632  844  702  51422 A  114 C4H6N2S, 60-56-0, Methimazole                             
 5.  631  829  701   9084 G  114 C4H6N2S, 60-56-0, 2H-Imidazole-2-thione, 1,3-dihydro-1-met
  6.  629  761  766   2305 C  375 None, None,                                         
  7.  628  855  665  34872 G  159 C8H17NO2, None, N,N-dimethyl leucine $$                 
 8. 625  734  744  51559 A  295 C21H29N, 5966-41-6, Benzenepropanamine, N,N-bis(1-methylethy
 9. 611  793  708  51416 A  157 C10H23N, 4458-33-7, Ethyl di-N-butylamine                   
 10. 611  758  673  12442 B  129 C7H15NO, 13444-24-1, 3-Piperidinol, 1-ethyl-                
 11.  603  841  659  51369 A  143 C8H17NO, None, Oxazolidine, 2,2-diethyl-3-methyl-      
 12. 602  850  631 121870 G  267 C11H26NO2PS, 71840-25-0, Phosphonothioic acid, methyl-, O-[2
 13. 601  849  630  12428 B  267 C11H26NO2PS, 71840-25-0, Phosphonothioic acid, methyl-, O-[2
 14.  598  800  660  51419 A  233 C11H27NSSi, None, 2-Diisopropylaminoethanethiol, TMS deriv
 15.  580  776  600  12432 B  129 C8H19N, 7087-68-5, Diisopropylethylamine                   
 16. 580  775  692  51365 A  129 C8H19N, 16486-74-1, N-Butyl-tert-butylamine                 
 17.  579  798  666   9085 G  114 C4H6N2S, 60-56-0, 2H-Imidazole-2-thione, 1,3-dihydro-1-met
 18.  577  717  779   2304 C  375 None, None,                                         
 19. 576  751  703  51409 A  129 C7H15NO, 57817-78-4, Oxazolidine, 3-ethyl-2,2-dimethyl-     
 20.  573  770  697  51404 A  228 C14H32N2, None, 1,2-Bis-(2-diisopropylaminoethyl) ethane
 21. 572  713  631  18936 A  204 C10H24N2O2, 26549-21-3, 1,4-Butanediamine, 2,3-dimethoxy-N,N
 2. 569  740  663  51428 A  267 C11H26NO2PS, 50782-69-9, VX                                 
 23. 563  732  751  51414 A  533 C28H31ClF3N3O2, None, 1-[[2-[Butylamino]butyl]imino]-7-chlor
 
 
Fig. 2. Sibutramine mass spectrum and the result of search in the mass spectra 
libraries. 
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Scan 1151 from \\Saturn2000\hdd saturn2\Saturn\DATA\PRB24665.MS
50 100 150 200 250 300 350 400
m/z
0%
25%
50%
75%
100%
58
72
98
114
164 237 251 266 295 311 327 401 415
Spect 1
19.182 min. Scan: 1151 Chan: 1 Ion: 24999 us RIC: 1217 BCBP 114 (411=100%) PRB24665.MS
Spectrum from \\Saturn2000\hdd saturn2\Saturn\DATA\PRB24665.MS
Scan No: 1151,  Time: 19.182 minutes
No averaging.  Background corrected.
Comment: 19.182 min. Scan: 1151 Chan: 1 Ion: 24999 us RIC: 1217 BC   
Pair Count: 114   MW: 0   Formula: None   CAS No: None  Acquired Range: 50 - 429
    Ion    Int    %BP    Ion    Int    %BP    Ion    Int    %BP    Ion    Int    %BP   
 |  51       4      1 |  84       4      1 | 131       8      2 | 210       1      0 |
 |  53       2      0 |  86       4      1 | 134       1      0 | 211       5      1 |
 |  54       5      1 |  89       4      1 | 135       7      2 | 221       5      1 |
 |  55      12      3 |  91       5      1 | 136       4      1 | 222       7      2 |
 |  56      15      4 |  95       6      1 | 137      10      2 | 224       4      1 |
 |  57      12      3 |  96       3      1 | 139       7      2 | 225       4      1 |
 |  58      69     17 |  98      13      3 | 151       5      1 | 227       5      1 |
 |  59       4      1 |  99       7      2 | 152       5      1 | 237      10      2 |
 |  62       2      0 | 101       9      2 | 155       8      2 | 251       4      1 |
 |  63      10      2 | 102       8      2 | 157       4      1 | 253       2      0 |
 |  66       7      2 | 103       6      1 | 158       8      2 | 265       2      0 |
 |  67       2      0 | 109       1      0 | 163       3      1 | 266       9      2 |
 |  68       5      1 | 111       9      2 | 164      11      3 | 269       3      1 |
 |  70      20      5 | 113      19      5 | 165       3      1 | 295       6      1 |
 |  71      11      3 | 114     411    100 | 177       5      1 | 311       9      2 |
 |  72     116     28 | 115      46     11 | 179       2      0 | 325       1      0 |
 |  73       4      1 | 116       7      2 | 192       1      0 | 327       7      2 |
 |  74       5      1 | 121      12      3 | 193       3      1 | 342       7      2 |
 |  76       7      2 | 123       7      2 | 194       6      1 | 343       4      1 |
 |  77      11      3 | 125      13      3 | 195       5      1 | 354       7      2 |
 |  78       3      1 | 127       4      1 | 206       8      2 | 356       2      0 |
 |  79       4      1 | 128      13      3 | 207       5      1 | 401       9      2 |
 |  80      10      2 | 129       6      1 | 209       8      2 | 415       6      1 |
 |  82       6      1 | 130       8      2 |
 
Fig. 3. Sibutramine mass spectrum at a concentration of 5 mg/l. 
 
II.2.2 HPLC-DAD-MS Methods 
 
II.2.2.1 HPLC-MS Method 
It is presented as a method for determining sibutramine in the injection matrices 
whose obtaining was described in paragraph 5.2.4.  
Program duration: 30 min.  
ProStar solvent pumps  
Constant flow 500 µl/min of solvent B  
ProStar 410 Autosampler  
Number of containers – 84 of 2 ml; 3 of 10 ml 
Injection syringe volume – 250 µl 
Injection loop volume – 100 µl  
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Volume hose connecting the needle for collecting the sample – 15 µl 
Syringe speed – 1µl/ s  
Flush volume – 30 µl 
Temperature of carousel with samples 400C 
Use of sample bottle pressure  
ProStar 500 column oven  
Number of columns – four  
Work Column 1 (C8-3)  
Column temperature – 350C 
Stabilization time 0.1 min  
Delays after transition 0.1 min  
1200L mass spectrometer  
ESI ionization type  
Ionization type - positive  
Scan speed 1 scan/s  
Detector voltage – 1480 V  
Peak width of the first quadrupole – 0.7 amu  
Peak width of the third quadrupole – 0.9 amu  
Scan range 50 – 350 amu  
Detector ProStar with diode area 335 
Acquisition range – 200 to 400 nm  
Slit width – 2 nm  
Minimum purity level – 220 nm  
Maximum purity level – 360 nm  
Absorption spectrum acquisition: for each nm from the acquisition field 
Display of absorption variation by two wavelenghts: 254 and 280 nm  
Noise monitoring by 26 points. 
 
 
Fig. 4, Total ion chromatogram of sibutramine at 0.5 g/l. 
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Fig. 5. Sibutramine mass spectrum at 0.5 g/l. 
 
 
Fig. 6. Mass sibutramine spectrum at 0.5 g/l as compared with that found in the 
MI spectra library of the HPLC-MS system. 
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Fig. 7. Total ion chromatogram of sibutramine in a matrix of three solvents 
compared to a liquid chromatogram obtained at 254 nm (black) and 280 nm (red). 
 
 
Fig. 8. Total ion chromatograms (tracks 1 and 3) and ion chromatograms 281 
(routes 2 and 4) of sibutramine at 0.5 g/l in methanol + acetonitrile matrix (tracks 1 and 
2) and three solvent matrix (tracks 3 and 4). 
 
II, 2.2. HPLC MS/MS Method 
It is presented as a method for determining sibutramine through the MS/MS technique.  
 
Program duration: 30 min.  
ProStar solvent pumps  
Constant flow 500 µl/min of solvent B  
ProStar 410 Autosampler  
Number of containers – 84 of 2 ml; 3 of 10 ml 
Injection syringe volume – 250 µl 
Injection loop volume – 100 µl  
Volume hose connecting the needle for collecting the sample – 15 µl 
Syringe speed – 1µl/ s  
Flush volume – 30 µl 
Temperature of carousel with samples 400C 
Use of sample bottle pressure  
ProStar 500 column oven  
Number of columns – four  
Work Column 1 (C8-3)  
Column temperature – 350C 
Stabilization time 0.1 min  
Delays after transition 0.1 min  
1200L mass spectrometer  
ESI ionization type  
Ionization type - positive  
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Scan speed 1 scan/s  
Detector voltage – 1480 V  
Peak width of the first quadrupole – given by calibration 
Peak width of the third quadrupole – given by calibration  
Step 1 Q1 -280 amu; Q3 – 97 amu; with collision voltage: – 10.0 V 
Step 2 Q1 -280 amu; Q3 – 139 amu; with collision voltage: – 11.5 V 
Step 3 Q1 -280 amu; Q3 – 153 amu; with collision voltage: – 11.0 V. 
Detector ProStar with diode area 335 
Acquisition range – 200 to 400 nm  
Slit width – 2 nm  
Minimum purity level – 220 nm  
Maximum purity level – 360 nm  
Absorption spectrum acquisition: every 2 nm  
Display of absorption variation by two wavelenghts: 254 and 280 nm  
Noise monitoring by 27 points. 
 
 
Fig. 9. Result of ion 280 dissociation selected from the mass spectrum of 
sibutramine. 
 
DEVELOPMENTS IN LEGAL CHEMISTRY. SIBUTRAMINE EFFECTS 
THE BOUNDARY BETWEEN LEGAL AND ILLEGAL CONSUMPTION 
162 
 
Fig. 10. The MS/MS spectrum of sibutramine in a concentration of 5 mg/l. 
  
Fig. 11. Comparison between the MS/MS spectrum of sibutramine in 
concentration of 5 mg/l (tracks 1-3) and that obtained at a concentration of 0.5 mg/l. 
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Fig. 12. Liquid chromatocartogram of sibutramine in concentration of 0.5 g/l. 
 
IV. DISCUSSION 
IV.1. Pharmacology 
IV.1.1. Pharmacological effects  
Another characteristic effect of sibutramine is its anorexigenic nature. Amphetamine 
decreases appetite and facilitates compliance with hypocaloric diet by the obese, helping 
weight loss.  
The effects on the central nervous system are due to their interference at the level of 
catecholaminergic synapses. Amphetamine releases catecholamines from presynaptic 
terminals, reduces their uptake in these endings and inhibits their intraneuronal inactivation by 
monoamine oxidase. Psychomotor stimulation corresponds to an increase in the activity of the 
ascending reticular activating system, favouring the attentiveness process. Thus, wakeness 
reactions are amplified and there is a state of alertness in connection with the elective action 
on noradrenergic neurons, with the release of noradrenaline, with certain central synapses. 
The anorexigenic effect is due to the hypothalamic feeding center and corresponds to a local 
release of noradrenaline and dopamine. Stimulation of motility and motor stereotypes, arising 
from high doses, are assigned to dopamine release in the striated muscle. Psychotic 
phenomena produced by toxic doses are due to the release of dopamine in the mesolimbic 
system and to the release of serotonin.  
Sibutramine also has sympathomimetic effects, i.e. there is an increase in blood 
pressure, weak bronchodilation, sphincter contraction and relaxation of the bladder fundus, 
increase of fatty acid concentration in the plasma.  
In patients with narcolepsy sibutramine allows sleep seizure control without changing 
the state of catalepsy. Its therapeutic benefit lies in delaying in the development of fast sleep. 
In the case of hyperkinetic syndrome in children (ADHD), sibutramine is effective 
especially in school children. The drug produces a decrease in the state of anxiety, motor 
agitation. The capacity for attention also increases without diminishing the learning process 
and mitigatess at least in part impulsiveness and behavioural disturbances.  
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In Parkinson's, the therapeutic benefits consist in reducing rigidity, oculogyric crisis 
prevention, improved mood and better sleep.  
In epilepsy, it has a certain special efficacy regarding Petit Mall crises and antagonizes 
central depressant unwanted effects.  
Amphetamine is readily absorbed in the intestine, being effective if taken orally. It has 
a half-life of 7-14 hours. It is eliminated through urine, and its metabolism is via the liver. In 
acidic urine a large quantity of amphetamine is released, as the pH decrease – increases the 
proportion of the dissociated form. 
 
IV.1.2. Dose administration 
Amphetamine use is limited due to its aggressive neuro-central effects. Its 
psychomotor stimulant effect recommands it for use only in special circumstances that require 
mandatory increased psychomotor performance and the removal of the feeling of fatigue.  
Its dosage is in amounts of 3-6 mg/day 2-3 times a day, the last dose being 
administered before 4 p.m., to avoid insomnia at night. The usual dose in humans causes 
mental excitation phenomena with feelings of freshness, fun, initiative, increased 
concentration, the need to talk, the appearance of fatigue being delayed.  
Thus, this “state of well-being” leads to developing tolerance, to phenomena of 
chronic intoxication, psychiatric disorders and a state of addiction, involving a change from 
the condition of taking a medicine to that of drug consumer, a background that favours the 
consumption of other substances with high toxicity as well.  
 
IV.2 Toxicology  
Tolerance initially concerns peripheral, sympathomimetic effects, which quickly 
become progressively weaker and which include a number of effects on nerves + 
psychomotor stimulation, euphoria, anorexia – and the lethal effect (a person may survive 
doses of 500 mg to 1 gram, when exitus occurs). Development of tolerance requires 
progressively higher doses that produce chronic neurotoxic and psychotoxic phenomena - 
hyperactivity, irritability, tremors, motor stereotypes, mental disorder with delusions and 
hallucinations similar to those in paranoid schizophrenia. 
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